Andrew Saik
CIK 1616284 · Chief Financial Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CHESTERBROOK, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARVN | Chief Financial Officer | 187,432 | $7.23 | $1.36M | -$261.6K | 8 | 2026-06-24 |
| MIST | Director | — | $0.65 | — | $0 | 4 | 2026-06-12 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | EVP & Chief Financial Officer | 68,265 | $19.00 | $1.30M | $0 | 10 | 2023-09-25 |
| VYNE Therapeutics Inc. (VYNE) Delisted | Chief Financial Officer | 129 | $28.56 | $3.7K | $58.5K | 4 | 2021-06-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Financial Officer | 300,000 | — | — | $0 | 2 | 2020-05-08 |
| PDSB | Chief Financial Officer | 42,549 | $1.09 | $46.6K | $0 | 3 | 2020-02-19 |
| EDGE | Chief Financial Officer | — | $52.10 | — | $0 | 4 | 2018-08-15 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | CFO | 0 | — | — | $0 | 2 | 2015-01-30 |
Recent Filings · Page 2 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-12 | MIST | Grant (A) | — | $0 | EDGAR |
| 2025-05-13 | ARVN | Grant (A) | +59,600 | $0 | EDGAR |
| 2025-02-18 | ARVN | Grant (A) | +49,092 | $0 | EDGAR |
| 2024-08-29 | MIST | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | MIST | Grant (A) | — | $0 | EDGAR |
| 2024-06-26 | ARVN | Grant (A) | +61,409 | $0 | EDGAR |
| 2023-11-13 | — | Mixed | −68,265 | -$1.30M | |
| 2023-09-25 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −908 | -$9.8K | EDGAR |
| 2023-06-23 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −908 | -$10.7K | EDGAR |
| 2023-03-23 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −909 | -$12.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.